315 Investigation Reveals "Exosome" Misconduct, Implicated Firm East West Aesthetic Hospital Faces Repeated Penalties

Deep News03-16

A recent 315 Gala exposé highlighted issues surrounding so-called "miracle" exosome treatments, naming Sichuan East West Aesthetic Hospital Co., Ltd. as a involved party. According to Tianyancha App, Sichuan East West Aesthetic Hospital Co., Ltd. was established in June 2008, with legal representative Lin Guoqiang and registered capital of 10 million RMB. Its business scope covers medical services, aesthetic medical services, lifestyle beauty services, and second-category value-added telecom services. The company is jointly owned by Meilai Medical Beauty Group Co., Ltd. and Xiamen Huayiguan Investment Co., Ltd. Public risk information indicates that in October 2025, the company was fined by the Chengdu High-tech Zone Market Supervision Administration for违规 content in its advertisements. Furthermore, in October 2024, it received a 30,000 RMB penalty from the Sichuan Provincial Market Supervision Administration for violations of the Advertising Law. Attempts were made to contact Sichuan East West Aesthetic Hospital Co., Ltd. via its business registration phone number. However, after the call was answered and the purpose of inquiring about the implicated "exosome" issue was stated, the other party hung up the phone without speaking.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment